CY1111754T1 - Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης - Google Patents

Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης

Info

Publication number
CY1111754T1
CY1111754T1 CY20111100757T CY111100757T CY1111754T1 CY 1111754 T1 CY1111754 T1 CY 1111754T1 CY 20111100757 T CY20111100757 T CY 20111100757T CY 111100757 T CY111100757 T CY 111100757T CY 1111754 T1 CY1111754 T1 CY 1111754T1
Authority
CY
Cyprus
Prior art keywords
composition
treatment
aminopyridine
release
sustained
Prior art date
Application number
CY20111100757T
Other languages
Greek (el)
English (en)
Inventor
Andrew R Blight
Lawrence Marinucci
Ron Cohen
Original Assignee
Acorda Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35061389&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1111754(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acorda Therapeutics, Inc. filed Critical Acorda Therapeutics, Inc.
Publication of CY1111754T1 publication Critical patent/CY1111754T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CY20111100757T 2004-04-09 2011-08-09 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης CY1111754T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56089404P 2004-04-09 2004-04-09
US11/102,559 US8354437B2 (en) 2004-04-09 2005-04-08 Method of using sustained release aminopyridine compositions
EP05732613.4A EP1732548B2 (en) 2004-04-09 2005-04-11 Methods of using sustained release aminopyridine compositions

Publications (1)

Publication Number Publication Date
CY1111754T1 true CY1111754T1 (el) 2015-10-07

Family

ID=35061389

Family Applications (4)

Application Number Title Priority Date Filing Date
CY20111100757T CY1111754T1 (el) 2004-04-09 2011-08-09 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης
CY2012004C CY2012004I2 (el) 2004-04-09 2012-01-19 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης
CY20131100351T CY1114073T1 (el) 2004-04-09 2013-04-29 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
CY2013035C CY2024026I2 (el) 2004-04-09 2024-07-30 Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY2012004C CY2012004I2 (el) 2004-04-09 2012-01-19 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης
CY20131100351T CY1114073T1 (el) 2004-04-09 2013-04-29 Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
CY2013035C CY2024026I2 (el) 2004-04-09 2024-07-30 Μορια προσδεσης pd-1 και μεθοδοι χρησης αυτων μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης

Country Status (21)

Country Link
US (13) US8354437B2 (enExample)
EP (5) EP2460521B1 (enExample)
JP (4) JP5736100B2 (enExample)
AT (1) ATE511841T1 (enExample)
AU (1) AU2005232732B2 (enExample)
CA (2) CA2870734C (enExample)
CY (4) CY1111754T1 (enExample)
DK (2) DK1732548T4 (enExample)
ES (2) ES2367707T5 (enExample)
FI (2) FI1732548T4 (enExample)
FR (1) FR13C0033I2 (enExample)
HR (2) HRP20110497T4 (enExample)
HU (1) HUE046320T2 (enExample)
LU (2) LU91933I2 (enExample)
ME (2) ME01721B (enExample)
MX (3) MX370434B (enExample)
PL (2) PL2377536T5 (enExample)
PT (2) PT2377536E (enExample)
RS (2) RS51808B2 (enExample)
SI (2) SI2377536T2 (enExample)
WO (1) WO2005099701A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
AU2013206188B2 (en) * 2005-09-23 2016-04-14 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
AU2009291781A1 (en) * 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
WO2010093839A1 (en) * 2009-02-11 2010-08-19 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) * 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) * 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
JP2014503596A (ja) * 2011-01-28 2014-02-13 アコーダ セラピューティクス，インコーポレーテッド 脳性麻痺を治療するためのカリウムチャネル遮断薬の使用
US8924325B1 (en) * 2011-02-08 2014-12-30 Lockheed Martin Corporation Computerized target hostility determination and countermeasure
US10793893B2 (en) 2011-06-30 2020-10-06 Serb Sa Methods of administering 3,4-diaminopyridine
TWI592156B (zh) 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
CA2864340A1 (en) 2012-02-13 2013-08-22 Acorda Therapeutics, Inc. Methods for treating an impairment in gait and/or balance in patients with multiple sclerosis using an aminopyridine
WO2014028387A1 (en) 2012-08-13 2014-02-20 Acorda Therapeutics, Inc. Methods for improving walking capacity in patients with multiple sclerosis using an aminopyridine
WO2014093475A1 (en) 2012-12-11 2014-06-19 Acorda Therapeutics, Inc. Methods for treating parkinson's disease using aminopyridines
ES2955137T3 (es) 2013-03-14 2023-11-28 Alkermes Pharma Ireland Ltd Profármacos de fumaratos y su uso en el tratamiento de diversas enfermedades
WO2014151752A1 (en) * 2013-03-15 2014-09-25 University Of Rochester Composition and methods for the treatment of peripheral nerve injury
CA2909527A1 (en) 2013-04-15 2014-10-23 Acorda Therapeutics, Inc. Methods for treating sensorimotor impairments associated with certain types of stroke using aminopyridines
SMT202100443T1 (it) 2015-02-08 2021-09-14 Alkermes Pharma Ireland Ltd Composizioni di profarmaci di monometilfumarato
RU2580837C1 (ru) * 2015-05-05 2016-04-10 Федеральное Государственное Автономное Образовательное Учреждение Высшего Профессионального Образования "Московский Физико-Технический Институт (Государственный Университет)" Кристаллогидрат 4-аминопиридина, способ его получения, фармацевтическая композиция и способ лечения и/или профилактики на её основе
US10172842B2 (en) 2015-09-11 2019-01-08 PharmaDax Inc. Sustained release oral dosage form containing dalfampridine
ES3008933T3 (en) 2015-09-29 2025-03-25 Merz Pharmaceuticals Llc Sustained release compositions of 4-aminopyridine
CA3059180C (en) 2017-04-06 2023-10-17 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1082804A (en) 1912-11-19 1913-12-30 Gerald G Griffin Confetti-machine.
US3065143A (en) 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
CH415963A (de) 1964-09-04 1966-06-30 Wander Ag Dr A Masse zur Herstellung von Tabletten mit protrahierter Wirkung
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4508715A (en) * 1981-07-01 1985-04-02 University Of Georgia Research Foundation, Inc. Antagonism of central nervous system drugs by the administration of 4-aminopyridine alone or in combination with other drugs
US4386095A (en) * 1982-02-22 1983-05-31 Cornell Research Foundation, Inc. Diaminopyridines to improve cognition
IE53703B1 (en) 1982-12-13 1989-01-18 Elan Corp Plc Drug delivery device
IE54286B1 (en) 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
IE56459B1 (en) 1983-12-21 1991-08-14 Elan Corp Ltd Controlled absorption pharmaceutical formulation
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US4894240A (en) * 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US4562196A (en) 1984-04-06 1985-12-31 Nelson Research & Development 2,4-Diaminopyridine as a pharmacologic agent
JPS6124516A (ja) 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4812447A (en) 1985-10-22 1989-03-14 City Of Hope Method for the treatment of nervous system degeneration
US4760092A (en) 1985-10-29 1988-07-26 The Rockefeller University Treatment of demyelinating diseases
US4832957A (en) 1987-12-11 1989-05-23 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
IL86170A (en) * 1987-05-01 1992-12-01 Elan Transdermal Ltd Preparations and compositions comprising nicotine for percutaneous administration
IE64726B1 (en) 1987-11-20 1995-08-23 Elan Corp Plc Pharmaceutical formulations for preventing drug tolerance
FI895821A7 (fi) * 1988-12-07 1990-06-08 The Wellcome Foundation Ltd Farmaseuttisesti aktivisia CNS-yhdisteitä
US4948581A (en) 1989-02-17 1990-08-14 Dojin Iyaku-Kako Co., Ltd. Long acting diclofenac sodium preparation
IE82916B1 (en) 1990-11-02 2003-06-11 Elan Corp Plc Formulations and their use in the treatment of neurological diseases
TW200462B (enExample) * 1990-09-27 1993-02-21 Hoechst Roussel Pharma
CA2085785C (en) 1992-12-18 2005-03-15 Robert R. Hansebout The use of 4-aminopyridine in the treatment of a neurological condition
DE4321030A1 (de) * 1993-06-24 1995-01-05 Bayer Ag 4-bicyclisch substituierte Dihydropyridine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimittel
US5451409A (en) 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5952357A (en) * 1993-12-23 1999-09-14 Cornell Research Foundation, Inc. Treating diseases of the anterior horn cells
US6284473B1 (en) * 1995-10-02 2001-09-04 Uab Research Foundation P-cresol sulfate, a component of urinary myelin basic protein-like material, as a correlate of multiple sclerosis status
US7179486B1 (en) 1997-04-01 2007-02-20 Nostrum Pharmaceuticals, Inc. Process for preparing sustained release tablets
US6288026B1 (en) * 1999-02-24 2001-09-11 Heinrich Exner Process and composition for treating diseases with an oil-in-water emulsion
US6600399B1 (en) 2002-02-05 2003-07-29 Roland Pierre Trandafir Transducer motor/generator assembly
WO2004082684A1 (en) 2003-03-17 2004-09-30 Acorda Therapeutics Stable oral formulations of aminopyridines and uses thereof
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
EP1651169A4 (en) * 2003-08-01 2008-02-27 Medarex Inc POLYTHERAPIES FOR MULTIPLE SCLEROSIS
US8007826B2 (en) 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
EP1888056A4 (en) * 2005-06-01 2008-09-03 Teva Pharma USE OF LADOSTIGIL FOR TREATING MULTIPLE SCLEROSIS
EP1940285B1 (en) 2005-09-23 2019-05-29 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
TWM331106U (en) * 2007-11-12 2008-04-21 Syspotek Corp Solution counter with temperature sensor
AU2009291781A1 (en) 2008-09-10 2010-03-18 Acorda Therapeutics, Inc. Methods of using sustained release aminopyridine compositions
WO2010090730A1 (en) 2009-02-03 2010-08-12 Acorda Therapeutics, Inc. Method, apparatus and software for identifying responders in a clinical environment
WO2010093839A1 (en) 2009-02-11 2010-08-19 Acorda Therapeutics, Inc. Compositions and methods for extended therapy with aminopyridines
JO3348B1 (ar) 2009-08-11 2019-03-13 Acorda Therapeutics Inc استخدام 4- بايريدين امينو لتحسين الادراك العصبي و/او التلف النفسي لدى مرضى يعانون من نقص النُخاعين وغير ذلك من امراض الجهاز العصبي
TW201125562A (en) 2009-09-04 2011-08-01 Acorda Therapeutics Inc Sustained release fampridine treatment in patients with multiple sclerosis
US10255905B2 (en) 2016-06-10 2019-04-09 Google Llc Predicting pronunciations with word stress

Also Published As

Publication number Publication date
WO2005099701A3 (en) 2006-03-23
JP2012188427A (ja) 2012-10-04
RS51808B2 (sr) 2023-12-29
JP5736100B2 (ja) 2015-06-17
US20180200241A1 (en) 2018-07-19
US20050228030A1 (en) 2005-10-13
JP5914626B2 (ja) 2016-05-11
SI1732548T1 (sl) 2011-09-30
US20140039015A1 (en) 2014-02-06
EP3922248A1 (en) 2021-12-15
MXPA06011648A (es) 2008-10-31
JP2015157861A (ja) 2015-09-03
LU91933I2 (fr) 2013-01-18
EP1732548B1 (en) 2011-06-08
AU2005232732B2 (en) 2011-05-12
PT2377536E (pt) 2013-04-11
SI2377536T2 (sl) 2022-11-30
EP1732548B2 (en) 2023-08-30
RS51808B8 (sr) 2019-08-30
CY2012004I1 (el) 2015-10-07
US20170071924A1 (en) 2017-03-16
CA2562277C (en) 2015-01-27
PT1732548E (pt) 2011-09-16
PL1732548T4 (pl) 2012-03-30
US20120064007A1 (en) 2012-03-15
ME01836B (me) 2014-12-20
CY2012004I2 (el) 2015-10-07
EP2460521A1 (en) 2012-06-06
AU2005232732A1 (en) 2005-10-27
US20110166187A1 (en) 2011-07-07
RS53371B (en) 2014-10-31
EP2377536A1 (en) 2011-10-19
EP2377536B2 (en) 2022-08-17
CY2013035I1 (el) 2020-05-29
US8440703B2 (en) 2013-05-14
CA2870734A1 (en) 2005-10-27
ES2746354T3 (es) 2020-03-05
US20170273960A1 (en) 2017-09-28
WO2005099701A2 (en) 2005-10-27
ATE511841T1 (de) 2011-06-15
MX2019015036A (es) 2020-02-24
CA2562277A1 (en) 2005-10-27
CA2870734C (en) 2022-08-16
FIC20130042I1 (fi) 2013-08-13
CY2024026I2 (el) 2025-03-28
LU92275I9 (enExample) 2019-01-03
LU92275I2 (fr) 2015-09-03
MX370434B (es) 2019-12-13
US20170209422A1 (en) 2017-07-27
DK2377536T3 (da) 2013-03-25
PL2377536T3 (pl) 2013-08-30
PL1732548T5 (pl) 2024-11-04
US20150080436A1 (en) 2015-03-19
EP1732548A4 (en) 2009-06-03
EP1732548B9 (en) 2012-03-21
ES2367707T9 (es) 2012-07-05
US9925173B2 (en) 2018-03-27
EP2460521B1 (en) 2019-06-12
HRP20110497T4 (hr) 2024-03-29
JP2015057451A (ja) 2015-03-26
US20120164078A1 (en) 2012-06-28
US20110166188A1 (en) 2011-07-07
DK1732548T3 (da) 2011-09-26
SI1732548T2 (sl) 2024-02-29
RS53371B2 (sr) 2022-11-30
PL2377536T5 (pl) 2023-03-06
DK2377536T4 (da) 2022-11-07
CY1114073T1 (el) 2016-07-27
DK1732548T4 (da) 2023-11-20
FI1732548T4 (fi) 2023-11-30
FR13C0033I1 (fr) 2013-08-09
EP2377536B1 (en) 2013-03-06
HRP20110497T1 (hr) 2011-08-31
HRP20130424T4 (hr) 2022-10-28
HUE046320T2 (hu) 2020-02-28
HK1162971A1 (en) 2012-09-07
US8354437B2 (en) 2013-01-15
PL1732548T3 (pl) 2011-11-30
EP2422782A1 (en) 2012-02-29
ES2367707T5 (es) 2024-04-25
FR13C0033I2 (fr) 2015-11-20
ES2367707T3 (es) 2011-11-07
HRP20130424T1 (en) 2013-06-30
US20110166189A1 (en) 2011-07-07
US20160199358A1 (en) 2016-07-14
RS51808B (en) 2011-12-31
RS51808B9 (sr) 2019-06-28
EP1732548A2 (en) 2006-12-20
SI2377536T1 (sl) 2013-07-31
ME01721B (me) 2014-09-20
JP2007532578A (ja) 2007-11-15

Similar Documents

Publication Publication Date Title
CY1111754T1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδeσμευσης
Kadriu et al. Glutamatergic neurotransmission: pathway to developing novel rapid-acting antidepressant treatments
Clayton et al. Comparison of sexual functional in clinical and nonclinical populations using the changes in Sexual Functioning Questionnaire (CSFQ)
Eslamian et al. The analgesic effect of benzocaine mucoadhesive patches on orthodontic pain caused by elastomeric separators, a preliminary study
UY32109A (es) Métodos para utilizar composiciones de liberación sostenida de aminopiridina
Everett et al. Arginine is a critical substrate for the pathogenesis of Pseudomonas aeruginosa in burn wound infections
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
ATE417604T1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
DE502004005154D1 (de) Multipartikuläre arzneiform, enthaltend mucoadhaesiv formulierte peptid- oder protein-wirkstoffe, sowie ein verfahren zur herstellung der arzneiform
EA200800161A1 (ru) Новые фармацевтические композиции с модифицированным высвобождением и способ получения таких композиций
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
Niebel et al. Successful treatment of psoriatic arthritis and comorbid annular atrophic lichen planus with etanercept
WO2005120542A3 (en) Methods of treating disease with random copolymers
BR0312507A (pt) Composições de medicamentos à base de novos anticolinérgicos e inibidores de egfr-cinase
DE602005010844D1 (de) Pharmazeutische zusammensetzungen mit interferon-tau
Takahashi et al. Toll‐like receptor 2 activation induces C‐C motif chemokine ligand 5 production in canine keratinocytes
EA200701010A1 (ru) Препарат гепирона с высокой дозировкой и длительным высвобождением
Matmuradov Impact Of Modern Types Of Treatment Dorsalgia Lumbosacral Spine On The Emotional Background Of Patients
RU2005107293A (ru) Способ лечения очагового и инфильтративного туберкулеза легких
CN105311387A (zh) 复方手参丸在制备治疗原发性震颤药物中的应用
Fitzpatrick et al. P012 Vidofludimus inhibits IL-17 and improves hapten-induced colitis in young rats by a unique dual mode of action
CN104784693A (zh) 蛋白激酶b抑制剂的新用途